Affimed is a clinical-stage immuno-oncology company focused on discovering and developing targeted cancer immunotherapies. Co.'s main candidate, AFM13, is an innate cell engager (ICE®) designed for the treatment of certain CD30-positive malignancies, including for both Hodgkin lymphoma and certain non-Hodgkin lymphomas. Co.'s second candidate, AFM24, is designed to address limitations, such as toxicities or treatment resistance, associated with existing therapeutic anti-epidermal growth factor receptor monoclonal antibodies. Co.'s third wholly-owned ICE® molecule, AFM28, was developed from its ROCK® platform and is designed to bind to CD123, an established target in myeloid malignancies. The AFMD average annual return since 2014 is shown above.
The Average Annual Return on the AFMD average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether AFMD average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AFMD average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free AFMD Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
